7/103 sources · 2 publishersUpdated Oct 23, 19:12 UTC
Novartis reports Phase III results for remibrutinib in relapsing multiple sclerosis
Novartis presented Phase III data for its multiple‑sclerosis drug remibrutinib, showing a 35.2% and 31.2% reduction in annual relapse rates versus Sanofi’s Aubagio. The company said the safety profile was favorable. Market commentary varied, with one source calling the data weaker‑than‑expected while another described disease control.
Why it matters
The efficacy results will shape analysts’ revenue forecasts for Novartis’s MS franchise, potentially influencing the stock’s valuation. Investors may adjust expectations for future sales and market share based on the reported relapse‑rate reductions.
Key facts
- 1Remibrutinib reduced annual relapse rates by 35.2% and 31.2% compared with Aubagio. ua.news
- 2Novartis’s share price moved 128.00 CHF over the prior 5‑day period. marketscreener.com
- 3The stock’s year‑to‑date change was +16.79%. marketscreener.com
- 4The 1 Jan change was –0.68%. marketscreener.com
Open questions
- One source described the data as weaker‑than‑expected, while another said it delivered disease control.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.